Dr Kalinsky on Differences in Efficacy Between CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Kevin Kalinsky, MD, MS, discusses differences in efficacy data for CDK4/6 inhibitors in the treatment of patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Related Keywords

Kevin Kalinsky ,Department Of Hematology ,Breast Cancer Research ,Winship Cancer Institute Of Emory University ,Glenn Family Breast Center ,Emory University School Of Medicine ,Medical Oncology ,Emory University School ,Breast Medical Oncology ,Rand Glenn Family Chair ,Winship Cancer Institute ,Emory University ,D ,Us ,Hr Positive ,Her2 Negative Breast Cancer ,Cdk4 6 Inhibitors ,Palbociclib ,Ribociclib ,Abemaciclib ,Paloma 2 ,Letrazole ,